Trials / Completed
CompletedNCT02163993
A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients With Episodic Migraine
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 414 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate whether the study drug known as galcanezumab is safe and effective in the prevention of migraine headaches.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Galcanezumab | Administered SQ |
| DRUG | Placebo | Administered SQ |
Timeline
- Start date
- 2014-07-07
- Primary completion
- 2015-08-19
- Completion
- 2018-02-12
- First posted
- 2014-06-16
- Last updated
- 2018-11-23
- Results posted
- 2018-11-23
Locations
40 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02163993. Inclusion in this directory is not an endorsement.